Clinical Trials Logo

Filter by:
NCT ID: NCT06170424 Completed - Morality Clinical Trials

Retrospective Analysis of Spray Skin Treats for Severe Burns

Start date: January 1, 2012
Phase:
Study type: Observational

This study investigated the efficacy of novel approach spray skin for extensive severe burns treatment.

NCT ID: NCT06170307 Active, not recruiting - COVID-19 Pandemic Clinical Trials

Left Atrial Function of COVID-19-recovered Patients During the Surge of Omicron Variants

Start date: November 20, 2023
Phase:
Study type: Observational

The goal of this observational study is to retrospectively analyze left atrial function in mild to moderate COVID-19-recovered patients. The main questions it aims to answer are: - Whether left atrial function is involved in patients with mild to moderate COVID-19 after recovery. - What are the factors that may be associated with persistent heart-related symptoms (including chest pain, chest tightness, palpitations, shortness of breath, or postural tachycardia) in patients with mild to moderate COVID-19 ? Participants will undergo transthoracic echocardiography to obtain conventional ultrasound parameters, two-dimensional strain parameters will been obtained through software post-processing, and general clinical data and laboratory test results will been obtained.

NCT ID: NCT06170294 Recruiting - Clinical trials for Advanced Solid Tumor

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Start date: January 1, 2024
Phase: Phase 1
Study type: Interventional

A single-arm, open-label, dose exploratory study to evaluate the safety, efficacy, and pharmacokinetics of autologous humanized anti-MAGE-A4 T cell receptor-engineered T cell (TCR-T) in advanced solid tumors.

NCT ID: NCT06170216 Active, not recruiting - Clinical trials for Lymphoma, Non-Hodgkin

Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL)

Start date: January 10, 2023
Phase:
Study type: Observational

Describe the application status of different immunochemotherapies in small B-cell non-Hodgkin lymphoma (iNHL), observe the therapeutic efficacy and safety of the treatment modalities.

NCT ID: NCT06170086 Active, not recruiting - Stroke, Acute Clinical Trials

Early Neurological Trajectory and Clinical Outcomes in Brain Acute Ischemic Stroke

Start date: September 1, 2023
Phase:
Study type: Observational

Prospective identification of potential responsible blood vessels, provision of intervention targets, prevention of fatal and disabling cerebrovascular diseases, identification of early END patients, determination of clinical treatment pathways, improvement of efficacy, and improvement of prognosis

NCT ID: NCT06170021 Recruiting - Clinical trials for Nasopharyngeal Carcinoma

Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Radiotherapy

Start date: December 6, 2023
Phase:
Study type: Observational [Patient Registry]

This is an observational cohort study to investigate the incidence of radiation-induced otitis media, changes in tubal function and hearing in newly diagnosed nasopharyngeal carcinoma patients without metastasis at multiple time points from baseline to 1 year after radiotherapy.

NCT ID: NCT06169995 Completed - Clinical trials for Sedation in the Upper Gastrointestinal Endoscopy

A Study of Remimazolam Tosilate for Sedation in the Upper Gastrointestinal Endoscopy

Start date: December 11, 2023
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Remimazolam Tosilate for Injection for sedation in Upper Gastrointestinal Endoscopy

NCT ID: NCT06169930 Completed - Survivorship Clinical Trials

Development and Validation of a Survival Prediction Model for Esophageal Cancer Patients After Esophagectomy

OSmodel
Start date: December 1, 2023
Phase:
Study type: Observational

In this retrospective study, we analyzed data from the Sichuan Cancer Hospital & Institute Esophageal Cancer Case Management Database (SCH-ECCM Database) from January 2010 to December 2017. Our study focused on examining the clinicopathological characteristics, lymph node removal at each station, and treatment details of patients with esophageal squamous cell carcinoma (ESCC) who underwent esophagectomy. Using this data, we developed a prediction model for OS by considering a combination of clinical characteristics and details of lymphadenectomy variables.

NCT ID: NCT06169579 Enrolling by invitation - Clinical trials for Advanced Solid Tumor

An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers

Start date: February 4, 2024
Phase: Phase 1
Study type: Interventional

This study is done to test the safety and preliminary efficacy of drug ND-003 tablets in patients with solid tumors. ND-003 is a highly potent and selective small molecular inhibitor of NTRK (neurotrophic receptor tyrosine kinase) and RET (rearranged during transfection). The study also investigates how the drug is absorbed and processed in the human body.

NCT ID: NCT06169475 Completed - Septic Shock Clinical Trials

Effect of Dexmedetomidine vs Esmolol or Placebo on Cerebral Hemodynamics in Septic Shock

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection. Some researchers proposed that the dysregulated response or organ dysfunction can be lessened by reducing the stress response, which further reduce complication and mortality rates of sepsis. Dexmedetomidine is alpha adrenergic receptor agonist, presenting sympatholytic action in certain parts of the brain with anxiolytic, sedative, and pain killing effects. In the experiments of sepsis animal model, dexmedetomidine have been proved to improve serum lactate clearance and the microcirculation. Dexmedetomidine may inhibit inflammation, as it enhances the activity of the immune system while reducing its systemic reaction and lowering cytokine concentrations. There are also evidences in clinical trials with definite safety that dexmedetomidine reduced inflammation, reduced vasopressor requirements and improved organ function. The beta antagonist esmolol has been proposed as a therapy to lower heart rate, thereby improving diastolic filling time, and improving cardiac output, resulting in a reduction in vasopressor support. A recent meta-analysis of 8 randomized studies using esmolol suggested that the 32% risk ratio decreased 28-day mortality, and a meta-analysis of 7 studies using esmolol in patients with sepsis and septic shock was associated with 32% lower 28-day mortality. However, the effect of anti-stress drugs on cerebral hemodynamics is unknown. In this study, investigators are going to apply the technique of transcranial Doppler to assess the reaction of cerebral blood flow in anti-stress group and control group.